Prostate cancer

PhD projects

 

Clinical projects

The PC Project

Criteria for the selection and treatment of clinically localised prostate cancer.

The main objective of the prostate cancer (PC) project is to improve the understanding of prostate cancer by utilising known and newly-developed methods. In a broad collaboration between units, departments and institutes, the objective is to contribute to reducing illness and morbidity in patients with clinically localised disease.

A secondary objective of the PC project is to establish a clinical database to assist with the quality control of diagnostics, staging of prostate cancer, operation (radical prostatectomy), therapeutical side effects, life quality, time of any relapses of the disease (biochemical, radiological) and surviving prostate cancer.

All patients who undergo surgery for removal of the prostate gland (radical prostatectomy) have had the opportunity to participate in the PC project since 2002. Approx. 2,100 patients contributed to the PC biobank with blood- and urine samples as well as tissue from the prostrate.

The PC project is being carried out in close collaboration with the Department of Molecular Medicine (MOMA)  Read more here

Primary responsibility: Professor, Consultant, DMSc, PhD Michael Borre

MDM

The overall objective of the project is to develop new non-invasive or minimally invasive molecular diagnostic methods for improved detection of prostate cancer and better prediction of the prediction of the future progression of the disease. Such methods will pave the way for a future reduction in overtreatment of prostate cancer. We will therefore:

  1. Systematically and prospectively collect blood-, urine- and prostate tissue samples from patients referred to prostate biopsy for diagnosis of prostate cancer
  2. Register all relevant clinical, paraclinical and histopathological parameters for these patients, as well as following them prospectively. For example, the result of initial/repeat prostate biopsies, response to any later treatment for prostate cancer, any disease progression or PSA increase, etc.
  3. Analyse specific molecular/candidate markers (e.g. miRNA, mRNA, DNA, DNA methylation, protein) in urine, blood and/or prostate biopsy tissue from the above-named patients and compare all molecular findings with relevant clinical, paraclinical and histopathological parameters including biopsy findings (positive=malign, negative=non-malign), tumour stage, Gleason classification, PSA etc.

The ultimate goal is thus to develop a molecular diagnostic test which with greater certainty than the existing methods can predict which patients actually need a prostate biopsy (initial/repeat), as well as which patients actually have prostate cancer that requires treatment. The final development of such a test will however require further studies in new multicentre studies.

The project is carried out in close collaboration with MOMA and approx. 1,500 patients are expected to participate in the project.
Read more about the project here.

Primary responsibility: Professor, Consultant, DMSc, PhD Michael Borre

Funding: The Danish National Advanced Technology Foundation has granted DKK 12.8 million to the project “Improved Molecular diagnostics for prostate cancer”, of which DKK 3.76 million goes to Aarhus University Hospital. Applications will be made for additional financial support for the project from other foundations.

Research coordinator for prostate cancer projects

Project nurses

Birgit Kaa Bach

Email: birgit.kaa.bach@rm.dk   
Tel: +45 78 45 26 37/ +45 30 91 55 82

Vibeke Laursen 

Email: vibeke.laursen@rm.dk   
Tel: +45 2477 8812

Project biomedical laboratory scientists

Derya Ayyildez

Email: deroez@rm.dk  
Tel: +45 24 60 82 92

Mette Korsgaard Emdal

Email: mettekud@rm.dk    
Tel: +45 30 91 11 97

PhD students